Critical to Sarepta’s outlook is whether Elevidys will get back on the market. TD Cowen analyst Ritu Baral wrote Monday that the voluntary suspension could last three to six months. A bearish Mitchell Kapoor, an analyst at H.C. Wainwright wrote Monday ...

Sarepta Therapeutics' recent setbacks and restructuring have pressured Arrowhead's share price. Read why I am reiterating my bullish rating on ARWR stock.

Sarepta faces FDA scrutiny over Elevidys as analysts downgrade stock and warn of long-term debt risks amid market uncertainty.

Analysts have set 12-month price targets for Sarepta Therapeutics, revealing an average target of $164.08, a high estimate of $185.00, and a low estimate of $128.00.

Sarepta Therapeutics, Inc. faces setbacks with Elevidys, safety issues, and workforce cuts, raising concerns about its outlook. Click for my SRPT stock update.

9 analysts have expressed a variety of opinions on Sarepta Therapeutics (NASDAQ:SRPT) over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table ...

Sarepta Therapeutics appears to have right-sized itself after laying off over a third of its staff, announcing a significant pipeline shift and adding a black box warning to its Duchenne muscular dystrophy gene therapy Elevidys.

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

Over the past 3 months, 6 analysts have published their opinion on Sarepta Therapeutics (NASDAQ:SRPT) stock. These analysts are typically employed by large Wall Street banks and tasked with ...

Across the recent three months, 26 analysts have shared their insights on Sarepta Therapeutics (NASDAQ:SRPT), expressing a variety of opinions spanning from bullish to bearish.The table below ...